ImmunityBio stock (US45258J1025): FDA accepts ANKTIVA bladder cancer filing and sets 2027 PDUFA date

ImmunityBio stock jumped after the FDA accepted a supplemental ANKTIVA filing for bladder cancer and set a PDUFA date for early 2027. What this could mean for the company’s commercial transition and US investors.

ImmunityBio stock drew renewed attention this week after shares gapped higher in US trading. The move followed news that the US Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for ANKTIVA in combination with BCG in bladder cancer and set a Prescription Drug User Fee Act (PDUFA) decision date for January 6, 2027, according to MarketBeat as of 05/20/2026.

In the same report, ImmunityBio shares were noted to have closed at 7.76 USD on the previous session and opened at 8.42 USD on Nasdaq after the announcement, underlining how closely investors are watching ANKTIVA’s regulatory progress, according to MarketBeat as of 05/20/2026.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ImmunityBio Inc
• Sector/industry: Biotechnology, oncology
• Headquarters/country: United States
• Core markets: Cancer immunotherapy in the US and selected international markets
• Key revenue drivers: ANKTIVA for bladder cancer and related oncology candidates
• Home exchange/listing venue: Nasdaq (ticker: IBRX)
• Trading currency: US dollar (USD)

ImmunityBio Inc: core business model

ImmunityBio focuses on developing and commercializing immunotherapies for cancer, with an emphasis on harnessing the body’s immune system to target tumors. The company has positioned itself at the intersection of oncology and immunology, aiming to offer alternatives for patients who have limited response to standard treatments, particularly in bladder cancer.

The foundation of ImmunityBio’s current strategy is ANKTIVA, a therapy that targets specific immune pathways in non-muscle invasive bladder cancer patients who do not respond adequately to traditional BCG treatment. With the FDA having already evaluated ANKTIVA for certain indications and now accepting a supplemental filing for use in combination with BCG, the company is moving further along the path from a pure clinical-stage developer to a more established commercial player, according to information from the company’s materials and recent regulatory announcements.

Beyond bladder cancer, ImmunityBio maintains a portfolio of clinical programs investigating the potential of its immunotherapy platforms in other tumor types. While these additional programs are at different stages of development, management has repeatedly emphasized a strategy of building a diversified pipeline around shared immune mechanisms, seeking to leverage scientific know-how across several cancer indications.

Main revenue and product drivers for ImmunityBio Inc

For now, ANKTIVA represents the central commercial and financial driver for ImmunityBio. The therapy is intended for patients with non-muscle invasive bladder cancer who have an inadequate response or intolerance to intravesical BCG, a standard treatment that has faced supply constraints in some markets. As regulators expand indications or combinations for ANKTIVA, the potential eligible patient population may increase, which investors often view as a key determinant for future revenue growth.

The latest FDA sBLA acceptance for ANKTIVA plus BCG, with a PDUFA date in early 2027, creates a multi-year regulatory roadmap that could shape the company’s revenue trajectory. If approved, the combination could strengthen ImmunityBio’s position in the bladder cancer treatment landscape, adding to earlier regulatory decisions and creating more opportunities for hospital adoption, according to MarketBeat as of 05/20/2026.

In parallel, ImmunityBio has been working on access programs and international expansion to support uptake of ANKTIVA. Such efforts, which can include compassionate use or expanded access pathways and launches in selected regions outside the US, are designed to build physician familiarity and real-world experience. Over the longer term, additional oncology indications under clinical investigation could provide new revenue streams, but they also require sustained investment in research, trials and potential manufacturing scale-up.

Industry trends and competitive position

The oncology biotechnology sector remains one of the most research-intensive segments of the healthcare industry, with numerous companies pursuing immunotherapy approaches. Checkpoint inhibitors, CAR-T treatments and cytokine-based therapies have all gained traction over the past decade, and major pharmaceutical groups continue to invest heavily in combination regimens. In this context, ImmunityBio is attempting to differentiate ANKTIVA through its mechanism of action and targeted focus on bladder cancer patients who are not adequately served by existing options.

Competition in bladder cancer includes established treatments as well as candidates from other biopharma companies that are investigating different immunotherapy approaches. Larger players often benefit from scale, broader pipelines and more resources for marketing and market access. For a mid-sized biotechnology company like ImmunityBio, building a strong niche position in specific indications and demonstrating clinically meaningful outcomes are critical to securing hospital adoption and reimbursement.

At the same time, regulators in the US and Europe are demanding robust evidence on efficacy and safety, which can lengthen timelines but also create high barriers to entry once a therapy is approved. The acceptance of the ANKTIVA plus BCG sBLA and the assignment of a PDUFA date shows that the FDA sees the submission as sufficiently complete for full review, a step that helps clarify regulatory risk for investors, according to MarketBeat as of 05/20/2026.

Why ImmunityBio Inc matters for US investors

For US investors, ImmunityBio offers exposure to the high-risk, high-uncertainty biotech space with a concentrated focus on cancer immunotherapy. The stock is listed on Nasdaq in US dollars, which facilitates access for US-based retail and institutional investors without currency conversion for the underlying shares. The catalyst-driven nature of biotechnology means that regulatory milestones, clinical readouts and partnership announcements can have a pronounced impact on the share price over short periods.

ImmunityBio’s ongoing shift from a primarily clinical-stage profile to a more commercial-stage business is another aspect that many US investors monitor closely. While commercial revenues can help reduce dependence on capital markets over time, the company still faces the funding demands of late-stage clinical trials and potential manufacturing scale-up. Understanding how ANKTIVA sales evolve and how regulatory decisions such as the 2027 PDUFA outcome unfold is therefore central to many investment theses around the stock.

Moreover, developments in the broader US healthcare policy environment, reimbursement frameworks for oncology drugs and competition from large pharmaceutical companies may influence ImmunityBio’s prospects. For investors who follow the sector, the stock can serve as an example of how a focused biotech seeks to build a sustainable franchise around a lead oncology asset while navigating regulatory and commercial challenges in the US market.

Conclusion

The recent gap up in ImmunityBio stock underlines how sensitive biotech valuations can be to regulatory milestones. With the FDA accepting the sBLA for ANKTIVA plus BCG in bladder cancer and setting a PDUFA date for early 2027, investors now have greater visibility on a key decision point that could affect the therapy’s commercial reach in the US. At the same time, the company remains exposed to typical biotechnology risks, including regulatory uncertainty, competitive pressure and the need to translate clinical promise into sustainable sales.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.